SunCorp is a small ($1bn) cap where 70+% of shares are basically locked up, and the main asset is a US listco. Illiquid. It trades at a discount. But CLBT US is down, so raw upside looks better.
What is covered in the Full Insight:
Introduction
Corporate Background
Current Value and Shareholder Structure
Potential Outcomes and Future Considerations
Conclusion and Trade Recommendation
Boomeranged on Fri, 12 Sep 2025 11:26
Since I wrote 3 weeks ago, CLBT is up 20%, Sun Corp is up 10%, the discount is wider. US domestic political stress will only increase the demand for Cellebrite's product and getting into the official USG procurement plan will only help. I expect that would encourage a potential buyer to want to own it. And that is the catalyst for Sun Corp value realisation. Sun Corp is still a buy here.